Safety and Efficacy of KPI-121 in Subjects With DED

NCT03616899 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

901

Enrollment

INDUSTRY

Sponsor class

Conditions

Kerato Conjunctivitis Sicca

Interventions

DRUG: KPI-121 Ophthalmic Suspension
DRUG: Vehicle

Sponsor

Kala Pharmaceuticals, Inc.